FDA Issues Warnings on Type 2 Diabetes Drugs

The FDA has issued a warning on Type 2 diabetes drugs that are currently being sold by AstraZeneca, Johnson & Johnson and Eli Lilly in partnership with Boehringer Ingleheim that could lead to much higher levels of blood acids resulting in hospitalization. The drugs are a class of drugs known as SGLT2 inhibitors. These drugs function by causing blood sugar to be secreted into the urine.


The drugs that have been included in the warning are AstraZeneca’s Farxiga (dapagliflozin), J&J’s Invokana (canagliflozin) and Jardiance (embagliflozin) from Lilly and Boehringer. The warning regarding the drugs was posted to the FDA website. The warning stated that the medicines could result in ketoacidosis for diabetes patients.

The FDA says that the warning is based on cases of acidosis that were reported to its Adverse Event Reporting System which included diabetic ketoacidosis, ketoacidosis, or ketosis in patients that had been treated using SGLT2 inhibitors during the period of March 2013 to June 6, 2014. The FDA also issued a warning against some combination Type 2 diabetes which had an SGLT2 drug listed as one of its components. These treatments included J&J’s Invokamet, Xigduo XR from AstraZeneca and Lilly and Boehringer’s Glyxambi

Next Post → ← Previous Post